Empagliflozin ameliorates diabetic cardiomyopathy via regulated branched-chain amino acid metabolism and mTOR/p-ULK1 signaling pathway-mediated autophagy

BACKGROUND: Empagliflozin, a sodium–glucose co-transporter 2 inhibitor (SGLT2i), has been reported to significantly reduce the risk of heart failure in multiple clinical studies. However, the underlying mechanisms remain elusive. This study aimed to investigate the effect of empagliflozin on branche...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Lin, Zhang, Heming, Xie, Xiuzhu, Tie, Ruping, Shang, Xiaolin, Zhao, Qianqian, Xu, Junjie, Jin, Liyuan, Zhang, Jinying, Ye, Ping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163822/
https://www.ncbi.nlm.nih.gov/pubmed/37149696
http://dx.doi.org/10.1186/s13098-023-01061-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10163822/
https://www.ncbi.nlm.nih.gov/pubmed/37149696
http://dx.doi.org/10.1186/s13098-023-01061-6

Ejemplares similares